Multicenter, double-blind, randomized clinical trial of parenterally administered Cefoselis versus Cefepime for the treatment of acute bacterial infections

• Published in: European review for medical and pharmacological sciences Vol. 18; no. 14; p. 2006
• Main Authors: Liu, Y-B, Lv, X-J, Yu, R-J, Qiu, H-M, Bai, J-L, Jiang, N, Lin, J-M, Liu, Y-J, Yan, H-Y, Song, S-D, He, P, Guo, D-Y, Li, X-S
• Format: Journal Article
• Language: English
• Published: Italy 2014
• Subjects: Acute Disease; Anti-Bacterial Agents - administration & dosage; Bacterial Infections - drug therapy; Ceftizoxime - administration & dosage; Ceftizoxime - analogs & derivatives; Cephalosporins - administration & dosage; Double-Blind Method; Female; Humans; Male; Respiratory Tract Infections - drug therapy; Urinary Tract Infections - drug therapy
• ISSN: 2284-0729

This study aims to evaluate the clinical efficacy and safety of intravenous Cefoselis injection for the treatment of acute moderate and severe bacterial infections.
A multicenter, double-blind, randomized clinical trial was carried out using Cefepime as control. Patients received 1.0 g of either Cefoselis or Cefepime for moderate infections or 2.0 g for severe infections at an interval of 12 hours for 7 to 14 days. A total of 276 patients (138 with Cefoselis, 138 with Cefepime) with respiratory or urinary tract infections were enrolled in the study. Up to 137 and 124 patients receiving Cefoselis and 132 and 125 patients receiving Cefepime were eligible for the ITT (intent to treat) and PP (per protocol) analyses, respectively.
At the end of the treatment, the cure rates and effective rates were 59.68% (74/124) and 93.55% (116/124) with Cefoselis, and 56.00% (74/124) and 90.40% (116/124) with Cefepime. The bacterial eradication rates of the two groups were 90.32% and 93.85%, respectively. No statistical differences were observed on the above-mentioned parameters between the two groups (all p > 0.05). Adverse events, mainly mild aminotransferase elevation and mild leukopenia, were observed in 11.59% (16/138) and 13.77% (19/138) of patients with Cefoselis and Cefepime, respectively (p > 0.05).
Cefoselis is an effective and safe choice against acute moderate and severe respiratory infections and UTI (urinary tract infection).